Detalles de la búsqueda
1.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
J Antimicrob Chemother
; 74(12): 3555-3564, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31430369
2.
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
Antimicrob Agents Chemother
; 60(2): 757-65, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26574015
3.
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
HIV Clin Trials
; 17(1): 29-37, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26899540
4.
Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Antimicrob Agents Chemother
; 59(6): 3441-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25824231
5.
Erratum to: Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
J Antimicrob Chemother
; 74(12): 3646-3647, 2019 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562501
6.
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
AIDS
; 38(7): 983-991, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38349226
7.
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Antimicrob Agents Chemother
; 57(6): 2654-63, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23529738
8.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
J Acquir Immune Defic Syndr
; 89(4): 433-440, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897227
9.
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
AIDS
; 36(11): 1511-1520, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35466963
10.
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
J Acquir Immune Defic Syndr
; 88(1): 86-95, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34397746
11.
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
J Acquir Immune Defic Syndr
; 85(3): 363-371, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32701823
12.
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet HIV
; 5(7): e357-e365, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29925489
13.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Lancet HIV
; 5(7): e347-e356, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29925490
14.
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
HIV Clin Trials
; 18(3): 118-125, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28555519
15.
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.
HIV Clin Trials
; 18(4): 141-148, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28689453
16.
Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
J Acquir Immune Defic Syndr
; 68(5): 519-26, 2015 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25559592
17.
Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Pediatr Infect Dis J
; 34(4): 398-405, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25599284
18.
HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
J Acquir Immune Defic Syndr
; 62(4): 367-74, 2013 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23187937
19.
HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.
J Acquir Immune Defic Syndr
; 79(1): e45-e51, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29781878
20.
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Antiviral Res
; 93(2): 288-296, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22197635
Resultados
1 -
20
de 20
1
Próxima >
>>